Skip to main content

CLL

4
Pipeline Programs
7
Companies
10
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
375%
Small Molecule
125%
+ 8 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
3 programs
3
EltrombopagPhase 2
OfatumumabPhase 2Monoclonal Antibody
Ofatumumab/HDMPPhase 2
Nordic Pharma
Nordic PharmaFrance - Paris
1 program
1
ibrutinib, venetoclax, obinutuzumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT04639362Active Not Recruiting85Est. Dec 2028
GSK
GSKLONDON, United Kingdom
3 programs
EltrombopagPHASE_21 trial
OfatumumabPHASE_2Monoclonal Antibody1 trial
Ofatumumab/HDMPPHASE_21 trial
Active Trials
NCT01168921Completed23Est. Mar 2022
NCT01465334Terminated30Est. Jan 2017
NCT01191190Completed21Est. Aug 2012
BeOne Medicines
BeOne MedicinesCA - San Carlos
2 programs
BGB-16673PHASE_31 trial
SonrotoclaxPHASE_32 trials
Active Trials
NCT06846671Recruiting250Est. Feb 2030
NCT06073821Active Not Recruiting652Est. Dec 2032
NCT04277637Active Not Recruiting437Est. May 2027
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
Treatment Free ObservationN/A1 trial
Active Trials
NCT04694560Withdrawn0Est. Mar 2023
TG Therapeutics
TG TherapeuticsNEW YORK, NY
1 program
TG-1801PHASE_11 trial
Active Trials
NCT04806035Terminated21Est. Jun 2024
Kyowa Hakko Kirin
Kyowa Hakko KirinCA - La Jolla
1 program
ZandelisibPHASE_2Small Molecule1 trial
Active Trials
NCT05209308Withdrawn0Est. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
BeOne MedicinesBGB-16673
BeOne MedicinesSonrotoclax
Kyowa Hakko KirinZandelisib
Nordic Pharmaibrutinib, venetoclax, obinutuzumab
GSKOfatumumab
GSKEltrombopag
GSKOfatumumab/HDMP
TG TherapeuticsTG-1801
BeOne MedicinesSonrotoclax
AbbVieTreatment Free Observation

Clinical Trials (10)

Total enrollment: 1,519 patients across 10 trials

NCT06846671BeOne MedicinesBGB-16673

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Start: Apr 2025Est. completion: Feb 2030250 patients
Phase 3Recruiting
NCT06073821BeOne MedicinesSonrotoclax

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Start: Nov 2023Est. completion: Dec 2032652 patients
Phase 3Active Not Recruiting
NCT05209308Kyowa Hakko KirinZandelisib

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

Start: Nov 2022Est. completion: Mar 20230
Phase 2Withdrawn
NCT04639362Nordic Pharmaibrutinib, venetoclax, obinutuzumab

CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

Start: Dec 2020Est. completion: Dec 202885 patients
Phase 2Active Not Recruiting
NCT01465334GSKOfatumumab

Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

Start: Dec 2011Est. completion: Jan 201730 patients
Phase 2Terminated
NCT01168921GSKEltrombopag

Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)

Start: Nov 2010Est. completion: Mar 202223 patients
Phase 2Completed
NCT01191190GSKOfatumumab/HDMP

Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)

Start: Aug 2010Est. completion: Aug 201221 patients
Phase 2Completed
NCT04806035TG TherapeuticsTG-1801

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Start: Apr 2021Est. completion: Jun 202421 patients
Phase 1Terminated
NCT04277637BeOne MedicinesSonrotoclax

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

Start: Mar 2020Est. completion: May 2027437 patients
Phase 1Active Not Recruiting
NCT04694560AbbVieTreatment Free Observation

A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Start: Dec 2020Est. completion: Mar 20230
N/AWithdrawn

Related Jobs

Associate Director, Oncology Lifecycle Management - Hematologic Oncology

NateraNatera
Remote
5d ago
$134K - $167K/yr

Strategic Alliance & Business Development Manager

Adaptive BiotechnologiesAdaptive Biotechnologies
Remote
1w ago
$129K - $193K/yr

Manager, Clinical Science

BeOne MedicinesBeOne Medicines
Remote
3w ago
$123K - $163K/yr

Director, Market Access Strategic Marketing

BeOne MedicinesBeOne Medicines
Remote
3w ago
$184K - $244K/yr

Medical Science Liaison - Quebec

BeOne MedicinesBeOne Medicines
Remote
3w ago

Sr. Director, Market Access Strategic Marketing

BeOne MedicinesBeOne Medicines
Remote
3w ago
$221K - $291K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,519 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.